MAM
Cinépolis launches first 7-screen multiplex in Bhubaneswar
MUMBAI: India’s first international theatre circuit, Cinépolis has launched its first multiplex equipped with seven screens in Esplanade One mall, Bhubaneswar, Odisha. The launch of the new cinema is in line with the company’s ambitious expansion plan and takes the total screen count of Cinépolis in India to 360.
As revealed by Cinépolis, the newly launched multiplex is armed with the latest technology and digital projection systems, set to offer consumers the best in-cinema experience. Additionally, the cinema is equipped with state-of-the-art 3-D technology from Real-D systems – the world's most widely deployed and advanced 3-D technology. The large legroom, a standard in all Cinépolis cinemas is designed to offer utmost comfort to patrons while they enjoy their movie.
Cinépolis Asia managing director Javier Sotomayor said, “We are delighted to launch our first multiplex in the beautiful city of Bhubaneswar. The demand for good-quality entertainment is only increasing, especially from tier II & III cities and we are building on this opportunity by bringing the unique Cinépolis experience to these markets. This launch is in line with our mission to expand our offerings and penetrate deeper into India.”
The flagship F&B brand from Cinépolis, Coffee Tree will offer a wide selection of gourmet food at the multiplex. All the audis in the multiplex has last two rows of VIP seating for a more luxurious and upgraded experience. Moviegoers can also enjoy the benefits of Club Cinépolis, the company's loyalty programme.
Cinépolis India director- strategic initiatives Devang Sampat said, “This multiplex is a first-of-its-kind in Bhubaneswar, equipped with enhanced sound system and VIP seats in all its auditoriums. With this launch, movie connoisseurs are sure to be enthralled with this unmatched experience along with enticing gourmet meals offered by the iconic ‘Coffee Tree’.”
Esplanade One Mall centre head Parth Pratim Nayak said, “Esplanade One is the biggest mall, not just in Bhubaneswar, but the entire state of Odisha. With Cinépolis now opening its door to our patrons, it will only add to our offerings and ensure a more complete experience. We are delighted to play host to Cinépolis and we are certain this will be a game changer for the Odisha market.”
MAM
Cipla appoints Achin Gupta as MD and global CEO
Veteran pharma leader with 20-plus years takes charge from 1 April 2026, succeeding current MD.
MUMBAI: Cipla’s next chapter just got a seasoned prescription because when it comes to leading a pharma giant, Achin Gupta knows exactly which dose delivers results. The Mumbai-based drugmaker announced on 23 February 2026 that Achin Gupta, currently global chief operating officer, will step up as managing director and global chief executive officer from 1 April 2026. He succeeds the outgoing leadership team and will steer Cipla’s worldwide operations, market expansion, operational efficiency, and innovation pipeline across its broad portfolio of generics, specialty drugs, and consumer healthcare treatments.
Gupta brings more than 20 years of pharmaceutical industry experience to the corner office. Before rejoining Cipla, he spent over eight years at Glenmark Pharmaceuticals in senior roles, having also worked there earlier between 2004 and 2012. His career path also includes key stints at Abbott Laboratories and management consulting firm A.T. Kearney, giving him a well-rounded view of global pharma strategy, operations, and growth.
In his current COO role, Gupta has already been deeply involved in streamlining Cipla’s supply chain, boosting manufacturing agility, and driving digital transformation moves that positioned the company strongly amid post-pandemic supply challenges and rising competition. As MD and Global CEO, he’ll now have full accountability for executing Cipla’s long-term vision, from deepening presence in key markets like the US, Europe, and emerging regions to accelerating R&D in complex generics and biosimilars.
The appointment comes at a pivotal time for Cipla, as the industry navigates pricing pressures, regulatory shifts, and the push for affordable innovation in chronic therapies. Gupta’s track record of scaling operations and delivering consistent performance makes him a logical internal choice to keep the momentum going.
For a company that’s long been a household name in affordable medicines, this leadership handoff is less about a big shake-up and more about steady continuity with fresh energy ensuring the next dose of growth is as effective as the last.
